All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Reduced-dose chemotherapy plus blinatumomab in patients with Ph− BCP-ALL: Results from a phase II trial
|
A phase II trial (NCT05557110) assessed the safety and efficacy of RDC plus blinatumomab as a first-line induction treatment in 35 patients aged 15–65 years with Ph− BCP-ALL.1 Patients received blinatumomab for 2 weeks, which was extended to 4 weeks in patients with no CR/CRi. Results from this trial were published in the Journal of Hematology & Oncology by Lu et al.1 |
| Key learnings |
|
RDC combined with 2 weeks of blinatumomab resulted in a CRc rate of 94%, with 86% of patients achieving MRD negativity. In two patients, blinatumomab treatment was extended to 4 weeks. For all patients with either 2 or 4 weeks of blinatumomab, CRc and MRD negativity rates were 100% and 89%, respectively. |
|
At a median follow-up of 11.5 months, the estimated 1-year PFS and OS rates were 82.2% and 97.1%, respectively. |
|
RDC plus blinatumomab was well tolerated, with no induction-related deaths within 4 weeks. Grade 3–4 neutropenia and thrombocytopenia occurred in 69% and 23% of patients, respectively. CRS occurred in 54% of patients, including Grade 3 CRS in 9% and ICANS (all Grade 1) in 14% of patients. |
|
These findings demonstrate the safety and efficacy of RDC plus blinatumomab as a first-line therapy for younger patients with Ph− BCP-ALL, suggesting that the adoption of less intensive, more targeted induction regimens may reduce chemotherapy-related toxicity while maintaining high remission and MRD negativity rates. Further studies are warranted to confirm these findings in larger populations with longer follow-ups. |
Abbreviations: BCP-ALL, B-cell precursor acute lymphoblastic leukemia; CR, complete remission; CRc, composite CR; CRi, CR with incomplete count recovery; CRS, cytokine release syndrome; ICANS, immune-effector cell-associated neurotoxicity syndrome; MRD, measurable residual disease; OS, overall survival; PFS, progression-free survival; Ph−, Philadelphia negative; RDC, reduced-dose chemotherapy.
- Lu J, Qiu H, Wang Y, et al. Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: A phase 2 trial. J Hematol Oncol. 2024;17(1):79. DOI: 1186/s13045-024-01597-8
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox